Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 4/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712741 | 1.00 | PYGL (0.40) | PYGLMCHR1VNN1MAP4K4LTA4H | |
| SCHEMBL21539706 | 0.89 | LMNA (0.38) | PYGLMCHR1VNN1MAP4K4LTA4H | |
| SCHEMBL21790197 | 0.83 | CCR5 (0.41) | PYGLVNN1DPP4DPP8USP30 | |
| SCHEMBL404146 | 0.79 | L3MBTL3 (0.35) | PYGLMCHR1 | |
| SCHEMBL1309093 | 0.79 | L3MBTL3 (0.35) | PYGLMCHR1 | |
| SCHEMBL13955505 | 0.79 | L3MBTL3 (0.35) | PYGLMCHR1 | |
| SCHEMBL21201850 | 0.76 | ADH1C (0.47) | PYGL | |
| SCHEMBL799469 | 0.76 | MCHR1 (0.43) | MCHR1VNN1MAP4K4LMNAHRH3 | |
| SCHEMBL8272497 | 0.76 | MCHR1 (0.43) | MCHR1VNN1MAP4K4LMNAHRH3 | |
| SCHEMBL21201804 | 0.76 | PYGL (0.33) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | claimed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | claimed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | PYGL 2325/4885MCHR1 1995/4885VNN1 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.